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Background: The exponential rise in published medical research on a yearly basis demands a method to
summarise best evidence towards its application to patient care in clinical practice. A robust meta-
analysis is a valid tool. It is often considered to be a simple process of pooling results from different
studies. This is not true. It appears that surgeons lack a reference guide to help them conduct and
appraise a meta-analysis.
Methods: This paper provides a structural framework to perform a meta-analysis. It guides the surgeon
on a journey from identiﬁcation of the correct clinical question to data analysis and through to producing
a structured report. Statistical methods are discussed brieﬂy as most commercial software calculates
most results in the background. An example of a recent meta-analysis is given. However, important
caveats are mentioned as there are limitations of the meta-analytical technique.
Conclusion: Whereas meta-analyses of homogeneous studies are the highest form of evidence, poorly
conducted meta-analyses create confusion and serve to harm the patient. Surgeons practising their art in
an era of evidence-based surgery need to understand the principles of meta-analyses.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Historically, surgical decisions have been made based on
personal experience, unquestioned use of methods suggested by
senior colleagues and recommendations from surgical authorities.
The progress of absorbing higher forms of evidence into the surgical
knowledge base has been slow. The proportion of systematic
reviews and randomised controlled trials (RCTs) in leading surgical
journals stands at 5%.1
To ensure the best possible outcomes for patients, clinicians are
increasingly required to implement best practices and continual
quality improvement processes in the clinical environment. This
inextricably involves the application of the best available knowl-
edge, usually in the form of scientiﬁc research, to guide clinical
decision making. Hence, the use of clinical research is no longer an
option but a necessity.k (S.S. Panesar), bhandam@
Darzi), t.athanasiou@imperial.
ciates Ltd. Published by Elsevier LtHowever, with increasing pressures of being a practising
surgeon and the reduction in the number of working hours,2 two
problems remain. One is the ability to synthesise and apply the best
evidence to improve patient care, bearing in mind that the average
clinicianwould have to read 19 original articles each day in order to
keep up with advances in his chosen ﬁeld.3 Conﬂicting or incon-
clusive results across individual research studies attributable to
a statistical play of chance or poorly designed study methodology
add further challenges to uncovering best evidence for clinicians.
Evidence synthesis is a highly valuable tool in health care which
can save clinicians valuable time and can also allow the best
evidence to be identiﬁed. Systematic reviews stand at the top the
hierarchical pyramid of evidence (level 1 evidence), when the
primary studies are all high quality (randomised trials) and
homogeneous in their results.4 Meta-analysis refers to the term
applied to systematic reviews with a quantitative combination of
results across two or more studies.5 Meta-analysis has become
a widely popular method of evidence synthesis.6 The increased use
of meta-analysis in the surgical literature has not been accompa-
nied by resources to ensure methodological rigor in its conduct nor
critical appraisal guides to assist clinicians in its interpretation. Our
aim is to provide a road-map for the essential steps involved in
conducting such a meta-analytical study.d. All rights reserved.
S.S. Panesar et al. / International Journal of Surgery 7 (2009) 291–2962921.1. The science of meta-analysis
A valid meta-analysis requires the same careful planning as any
other research study. The goals of a meta-analysis include a rele-
vant clinical question, explicit eligibility criteria, a comprehensive
search for best evidence, the rationale quantitative summary of the
data, and an explanation of variability between studies.
1.2. Deﬁning the objectives of the study
A well built clinical research question is the critical ﬁrst step of
a meta-analysis. The acronym widely used to remember a good
clinical question is P.I.C.O. For a therapeutic intervention, this
includes a description of the study population, the intervention,
a comparison group, and the outcome.
1.3. Deﬁning the population of studies to be included
A discrete and objective statement of inclusion and exclusion
criteria for studies should be provided. A priori inclusion and
exclusion criteria help to eliminate selection bias in the meta-
analysis. Any inclusion criteria must include:
 The study type – it must be decided from the onset whether
only randomised controlled trials (RCTs) or observational
studies will be included, although this remains debatable.7,8 A
meta-analysis is only as good as the quality of the primary
studies incorporated into it.9
 Patient characteristics – these include age, gender, ethnicity,
presenting condition, co-morbidities, duration of illness and
method of diagnosis.
 Treatment modalities – for the condition in question, the
allowable treatment type, dosage, duration and conversion
from one treatment to another should be addressed.1.4. Deﬁning the outcome measures
The protocol of the meta-analysis should explicitly specify the
key outcomes. Only one set of results from a single study should be
included even if multiple publications are available in order to
avoid duplication of the data set. Usually in these circumstances,
the data included will be from the latest publication or the paper
with the most complete data on the outcome measures of interest.
The outcome should generally be the most relevant and patient-
important.
1.5. Locating all relevant studies
This involves using a structured search strategy involving
databases such as NLH Medline, PubMed, EMBASE, CINAHL and
Google scholar. There are different search strategies for the various
databases and effective use must be made of MeSH headings,
synonyms, and the ‘related articles’ function in PubMed. Beyond
databases, researchers can ﬁnd potentially relevant papers in the
proceedings handbooks of medical meetings, bibliographies of
journal articles, textbooks, and experts in the ﬁeld. These form part
of the ‘grey literature’ an often useful but missed source of data.
1.6. Screening, evaluation and data abstraction
A rapid review of the abstracts of the papers will eliminate those
that are ﬁt for exclusion because of inadequate study design,
speciﬁc population, or duration of treatment or date of the study.
When available written information is insufﬁcient for the meta-analysis, efforts must be made to contact the principal investigator
to obtain the needed information to reduce the effects of publica-
tion bias.10
Usually it is recommended that two or more independent
observers then extract the data from the studies using a pre-
designed data extraction form to avoid errors. Patient demo-
graphics, baseline characteristics and clinical outcomes of interest
should be extracted and a table created, that shows all variables and
their values from all included studies.
The validity of the included studies should be assessed. While
several quality indices exist for the evaluation of surgical trials, the
use of a single index remains controversial. Juni et al. have reported
that different systems can lead to different interpretations of study
quality. Nevertheless, scores may be used to develop thresholds for
inclusion of studies.11,12 Blinding observers to the names of the
authors and their institutions, the names of the journals, sources of
funding, and acknowledgments can lead to more consistent
scores.11
1.7. Choose and standardise the outcome of measure
Individual results have to be expressed in a standardised format
in order to compare the studies. If the end point is continuous such
as the length of hospital stay after bypass surgery, the mean
difference (weighted mean difference, WMD) between the treat-
ment and control groups is used. The size of a difference, however,
is inﬂuenced by the underlying population characteristics. Differ-
ences are therefore often presented in units of standard deviation.
These data are presented in a forest plot as shown in Fig. 1. We
have chosen to look at the age-stratiﬁed mortality in off-pump
cardiopulmonary bypass (OPCAB) surgery versus on pump cardio-
pulmonary bypass (ONCAB) surgery.
If the end point is binary or dichotomous, such asmortality or no
mortality, then the odds ratio (OR) or relative risk or risk ratio (RR)
is calculated.
The OR is the probability that a particular event will occur to the
probability that it will not occur, and can be any number between
zero and inﬁnity. Risk describes the probability with which a health
outcome (usually an adverse event) will occur. Measures of relative
effect express the outcome in one group relative to that in the other.
For treatments that increase the chances of events, the odds ratio
will be larger than the risk ratio, so the tendency will be to
misinterpret the ﬁndings in the form of an overestimation of
treatment effect. For treatments that reduce the chances of events,
the odds ratio will be smaller than the risk ratio, so that again
misinterpretation overestimates the effect of treatment. This error
in interpretation is unfortunately quite common in published
reports of individual studies and systematic reviews.13
Absolute measures, such as the absolute risk reduction or the
number of patients needed to be treated (NNT) to prevent one
event are more helpful when applying results in clinical practice.14
The NNT can be calculated as 1/risk difference (RD).
1.8. Statistical methods for calculating overall effect
This involves calculating overall effect by combining the data.
The results from small studies are more subject to the play of
chance and should therefore be given less weight. Methods used for
meta-analysis use a weighted average of the results, in which the
larger trials have more inﬂuence than the smaller ones.
2. Fixed and random effects models
Two models can be used to assess the way in which the vari-
ability of the results between the studies.15
Fig. 1. Example of a Forest plot. 28
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The ‘‘ﬁxed effects’’ model considers that this variability is
exclusively due to random variation, i.e. if all the studies were
inﬁnitely large they would give identical results.
Methods of ﬁxed effect meta-analysis are based on the mathe-
matical assumption that a single common (or ‘ﬁxed’) effect
underlies every study in the meta-analysis, i.e. in a meta-analysis of
odds ratios, we would assume that every study is estimating the
same odds ratio. Under this assumption, if every study were inﬁ-
nitely large, every study would yield an identical result.16 Thus, the
summary measure is a simple weighted average and can be easily
interpreted as an estimate of a single population outcomemeasure.
The 95% CI will reﬂect only the variability between patients; hence,
with this class of methods, the 95% CI will be very narrow with
more power to reject the null hypothesis. The ﬁxed effects analysis
may be justiﬁed when the test for heterogeneity is not signiﬁcant;
i.e. when there is no evidence of major differences among studies.
In the ﬁxed effects analysis, the methods used to analyze binary
outcomes are the general inverse-variance method, the Mantel–
Haentzel method17,18 and the Peto method.152.2. Random effects model
The ‘‘random effects’’ model assumes a different underlying
effect for each study and takes this into consideration as an addi-
tional source of variation, which leads to somewhat wider conﬁ-
dence intervals than the ﬁxed effects model.19 Effects are assumed
to be randomly distributed, and the central point of this distribu-
tion is the focus of the combined effect estimate. When there is
some statistical heterogeneity, as detected by a statistically signif-
icant heterogeneity test, it will be implausible to assume that the
95% CI or imprecision of the summary outcome reﬂects only
between-patient variability. Therefore, the ﬁxed effects model willnot ﬁt the observed data well as the 95% CI will be too narrow. In
the random effects analysis, it is assumed that all the studies are
fundamentally different and that the outcome of a study will esti-
mate its own unique outcome, which differs from that of the other
studies. Hence, each study outcome is not assumed to ﬂuctuate
around a ﬁxed, common population outcome but to ﬂuctuate
around its own true value. It is assumed, however, that each of
these true values is drawn ‘‘randomly’’ from some underlying
probability distribution; i.e. that of a ‘‘superpopulation’’, commonly
assumed to be a normal distribution; hence, the name ‘‘random’’
effects analysis. That is, under a random effects assumption, not
only is each study performed on a sample drawn from a different
population of patients but that each of these populations is still
taken randomly from a common ‘‘superpopulation’’. A random
effects analysis makes the assumption that individual studies are
estimating different treatment effects; hence, the 95% CI in
a random effects analysis, reﬂecting the overall variability in the
data will be wider than that of a ﬁxed effects analysis because of
both inter-patient variability and inter-study variability.16
Both these individual statistical methods have their limitations
and a substantial difference in the combined effects calculated by
ﬁxed and random effect models will be seen only if studies are
markedly heterogeneous.2.3. Heterogeneity between study results
Sometimes, the variance between the overall effect sizes in each
study might not be due to random sampling variation but instead
could be due to the presence of other factors inherent within
individual studies. This effect size variation due to slightly different
study designs is termed heterogeneity. If the result of each study
differs greatly from each other and is deemed to be largely due to
heterogeneity, then it may not be appropriate to conduct a meta-
analysis in the ﬁrst place. If a test for homogeneity shows
Fig. 2. Funnel plots.
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assumed to be a consequence of sampling variation, and a ﬁxed
effects model is appropriate. If, however, the test shows that
signiﬁcant heterogeneity exists between study results then
a random effects model is advocated. If there is excess heteroge-
neity, then not even the random effects model could compensate
for this and the viability of the meta-analysis should be questioned.
A major limitation with heterogeneity tests is that these statistical
tests will lack power to reject the null hypothesis of homogeneous
results even if substantial differences between studies exist. After
signiﬁcant heterogeneity has been discovered, the causes and
sources of this need to be explored in detail.16
Various statistical tests are used to assess for heterogeneity. A
useful statistic is I2¼ [(Q df/Q)] 100, where Q is the chi-square
statistic and df is its degree of freedom. This statistic deﬁnes
variability along a scale-free range as a percentage from 0 to 100%.
This describes the percentage of the variability in effect estimates
that is due to heterogeneity rather than sampling error (chance).16
Typically, I2 values above 40% suggest substantial heterogeneity
and challenge the rationale to pool data across studies.
2.4. Funnel plots
Funnel plots aid to graphically reveal the presence of publication
bias – being a scatter plot function of study effect size and esti-
mated effect size.20,21 The premise being that larger studies will
have result estimates that are more precise while the contrary for
small studies is true. In an ideal settingwhere all possible published
and unpublished trials are available, individual studies would form
a symmetrical inverted funnel with more precise results from
larger trials bunched up at the top and less precise results from
smaller trials scattered symmetrically across. This is shown in Fig. 2.
An asymmetrical distribution can occur usually represented by
a deﬁciency in a certain region of the funnel that can be attributed
to the skewed distribution of studies created from publication or
reporting bias.20
2.5. Forest plots
Results from each trial, together with their conﬁdence intervals,
can be graphically displayed in a useful manner on a forest plot. A
black square and a horizontal line, which corresponds to the point
estimate and the 95% conﬁdence intervals of the outcome measure
respectively, represent each study. The dotted vertical line corre-
sponds to no effect of treatment (e.g. an odds ratio or relative risk of
1.0). If the conﬁdence interval includes 1, then the difference in the
effect of experimental and control treatment is not signiﬁcant at
nominally tolerated levels (P> 0.05). The size (or area) of the black
squares reﬂects the weight of the study in the meta-analysis while
the diamond represents the combined odds ratio, calculated using
a ﬁxed effects model, at its centre with the 95% conﬁdence interval
being represented by its horizontal.22
Most of the studies, if they are homogenous in design and
population would have overlapping conﬁdence intervals. However,
if the conﬁdence intervals of two studies don’t overlap at all, there
is variation between the two studies which is not likely due to
chance and likely due to the presence of heterogeneity. Other than
graphically using a forest plot, a numerical method could be ach-
ieved via use of the (c2) chi-squared test.16
2.6. Sensitivity analysis
This procedure assesses the robustness of the ﬁndings of the
meta-analysis. Both ﬁxed and random effects models should be
used. The methodological quality of studies should be assessed onone of the existing scoring scales or an arbitrary quality scale. The
meta-analysis can be repeated for high and low quality studies.
Signiﬁcant results are more likely to get published than non-
signiﬁcant ones, i.e. publication bias, which can distort the results
of a meta-analysis. Its presence can be identiﬁed by stratifying the
analysis by study size. Smaller effects can be signiﬁcant in larger
studies. If publication bias is present, it is expected that, of the
published studies, the larger ones will report the smallest effects
and the smallest ones may report the largest effects. If exclusion of
the smaller studies does not signiﬁcantly affect the overall estimate
of themeta-analysis, the sensitivity analysis conﬁrms the validity of
the meta-analysis, i.e. it is not affected by exclusion of trials of poor
quality.23
2.7. Subgroup analysis
The principal aim of meta-analysis is to produce an estimate of
average effect seen in trials of a particular treatment or interven-
tion. The clinician must make a decision as to whether his or her
patient is comparable to the patient group in themeta-analysis. The
meta-analysis may show superiority of one intervention over
another in only particular subgroups, when this analysis is under-
taken, but no difference between the two groups when the
subgroups are not analysed separately. Subgroup analysis could
also be used to explain heterogeneity by determining which
component of the study design may be contributing to treatment
Fig. 3. Overall pathway of systemic review/meta-analysis.
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caution.
The steps involved in performing ameta-analysis are outlined in
Fig. 3.
3. Discussion
In this paper, we have provided a broad outline of the proce-
dures for performing a meta-analysis in a systematic fashion.
However, this process should be performed with great care bearing
in mind that poorly conducted meta-analysis is of limited value to
the surgical literature.
Meta-analysis, especially surgical meta-analysis, is often an
exercise in compromise. It should not be seen as an opportunity to
pool results of different surgical studies that are dissimilar. For
example, inclusion of only experimental trials may exclude the
most contemporary literature, or an attempt to include all available
evidence may introduce heterogeneity. Compromise requires
qualitative value-judgements that even underpin a statistically
robust meta-analysis with a comprehensive literature review. This
does not necessarily demean the efﬁcacy of meta-analysis as a tool
for literature review, evidence synthesis and clinical decision
making; however it is imperative that these value-judgements are
explained and justiﬁed. Assessing the various dimensions of quality
is important. Unfortunately, this is often not the case.
The advantages of well-conducted meta-analyses are that they
allow objective appraisal of the evidence in comparison with
traditional narrative reviews, provide a more precise estimate of
a treatment effect, and may explain heterogeneity between the
results of individual studies. The application of meta-analysis in
surgery however is problematic and surgical meta-analyses are
often vulnerable to bias. Patient population characteristics, tech-
nological development and evolving surgical expertise have the
potential to signiﬁcantly affect event rates which can bias the
results of meta-analysis.25
There are numerous instances, where meta-analyses have
pooled results from small trials with disparate results, and as
a result have produced conﬂicting evidence. Furthermore, results
have been generated that were in conﬂict with the results of
subsequent large randomised clinical trials.26,27 When this occurs,
the reliability of the evidence is questioned resulting in poorly
guided clinical decisions. As a result, doubts have been raised about
the reliability of using meta-analyses to guide clinical practice.
Whilst even advocates of meta-analysis argue that it is not
a substitute for the clinical trails, it may be a useful guide to clinical
decision makers until unequivocal experimental evidence is avail-
able. However, if meta-analysis is to continue to have a role in
surgical decision making, surgeons needs to be able to perform,
assess, compare and communicate the quality of meta-analyses,
particularly in areas where several meta-analyses are available.
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